Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. I-Mab
  6. News
  7. Summary
    IMAB   US44975P1030

I-MAB

(IMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

I-Mab : to Provide Business and Corporate Updates and Report Financial Results for the Six Months Ended June 30, 2021 on August 31, 2021

08/17/2021 | 08:01am EDT

SHANGHAI and GAITHERSBURG, Md., Aug. 17, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced it will provide business and corporate updates and report financial results for the six months ended June 30, 2021, before the market opens on Tuesday, August 31, 2021. The Company's management will host conference calls to discuss the results and updates.

On August 31, 2021, a Mandarin session conference call will be held at 7:00 a.m. ET, and an English session conference call will be held at 8:00 a.m. ET. The conference calls can be accessed by the following Zoom links:

Mandarin Session

Meeting URL:

https://zoom.us/j/96267698618?pwd=S3p1NzZqdzdtQnZmS2lEbUpkeGk5Zz09 

Meeting ID:

962 6769 8618

Password: 

781902

English Session

Meeting URL:

https://zoom.us/j/99563840425?pwd=VTNTbUNFOHJhY1ptZFpkbU93WDBKUT09 

Meeting ID:

995 6384 0425

Password: 

819127

About I-Mab

I-Mab (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on discovery, development, and soon commercialization of novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. The Company's mission is to bring transformational medicines to patients around the world through innovation. I-Mab's innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the Company's Fast-to-PoC (Proof-of-Concept) and Fast-to-Market development strategies through internal R&D and global partnerships. The Company is on track to transition from a clinical-stage biotech company toward a fully integrated global biopharmaceutical company with cutting-edge R&D capabilities, world-class GMP manufacturing facilities, and commercial capability. I-Mab has offices in Beijing, Shanghai, Hangzhou, Hong Kong, and Maryland, United States. For more information, please visit http://ir.i-mabbiopharma.com and follow I-Mab on LinkedIn, Twitter, and WeChat.

For more information, please contact:

I-Mab

Jielun Zhu, Chief Financial Officer
E-mail: jielun.zhu@i-mabbiopharma.com
Office line: +86 21 6057 8000

Gigi Feng, Chief Communications Officer
E-mail: gigi.feng@i-mabbiopharma.com
Office line: +86 21 6057 5709

Investor Inquiries:

The Piacente Group, Inc.
Emilie Wu
E-mail: emilie@thepiacentegroup.com
Office line: + 86 21 6039 8363

Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-to-provide-business-and-corporate-updates-and-report-financial-results-for-the-six-months-ended-june-30-2021-on-august-31-2021-301356683.html

SOURCE I-Mab


© PRNewswire 2021
All news about I-MAB
10/19I MAB : Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combinati..
PU
10/18I MAB : Gets IND Approval to Conduct Mid-Stage Cancer Drug Trial in China
MT
10/18I-MAB : Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combinati..
PR
10/18I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combinat..
CI
10/15I MAB : Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (T..
PU
10/13I MAB : Completes Patient Enrollment in Phase 3 Study of Multiple Myeloma Therapy
MT
10/13I-MAB : Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (T..
PR
10/13I-Mab Advances Late-Stage Development of Its Differentiated CD38 Antibody Felzartamab i..
CI
10/05I-MAB : and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at th..
PR
10/05I-Mab and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at t..
CI
More news
Analyst Recommendations on I-MAB
More recommendations